Psychedelic research has surged in recent years, sparking enthusiasm among clinicians, investors and the general public. Clinical trials are indicating transformative outcomes for people struggling with mental illnesses like depression, post-traumatic stress disorder and end-of-life anxiety.
Recently, the spotlight is turning to eating disorders (ED), a group of severe and difficult-to-treat conditions. A survey revealed that 70 per cent of people view psychedelic medicine as a promising avenue for EDs and numerous reports depict positive results.
